phrykt

Ligand Pharmaceuticals Inc (LGND): who owns it and who trades it

As of Nov 16, 2026, LGND insiders reported 151 open-market sales worth $36.5M and no purchases in the last 12 months, with 70% of the sale value made under pre-set 10b5-1 plans. The largest seller was Octavio Espinoza (CFO), with $13M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Ligand Pharmaceuticals

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Funds, famous investors and Congress mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns LGND

414 funds and institutions reported LGND shares worth $7.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 15.5%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.15.5%
Invesco Ltd.6.0%
Vanguard Portfolio Management LLC5.7%
Jupiter Topco LLC5.2%
Vanguard Capital Management LLC4.3%
State Street Corp4.1%
FMR LLC (Fidelity)3.8%
Franklin Resources Inc3.8%
Congress Asset Management Co3.3%
Geode Capital Management, LLC2.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.3.10M15.47%$980M+5%
Invesco Ltd.1.20M6.00%$380M+46%
Vanguard Portfolio Management LLC1.14M5.68%$360M+3%
Jupiter Topco LLC1.04M5.19%$329M–
Vanguard Capital Management LLC870,9504.35%$275M+3%
State Street Corp826,5394.12%$261M+6%
FMR LLC (Fidelity)762,8273.81%$241M+28%
Franklin Resources Inc752,0443.75%$238M+31%
Congress Asset Management Co659,9113.29%$209M+31%
Geode Capital Management, LLC589,0202.94%$186M+5%
Nomura Asset Management International Inc.568,3712.84%$180M-1%
Chicago Capital, LLC553,4352.76%$175M-1%
Stephens Investment Management Group LLC475,6092.37%$150M-4%
Dimensional Fund Advisors LP429,3142.14%$136M+1%
Massachusetts Financial Services Co375,7621.87%$119M-9%
Goldman Sachs Group Inc323,2451.61%$102M-15%
Loomis Sayles & Co L P291,8051.46%$92.2M-17%
Rice Hall James & Associates, LLC270,0521.35%$85.4M-5%
Ranger Investment Management, L.P.257,5961.29%$81.4M-4%
Northern Trust Corp257,3891.28%$81.4M+1%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, LGND insiders reported $0 of open-market purchases and $36.5M of sales. 70% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$36.5M
151 trades, 8 people
Sales under a 10b5-1 plan
70%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 16, 2026

Purchases and sales by month

$12.8M$12.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026John W KozarichDirectorSale plan500$325.00$162KForm 4
Nov 12, 2026Martine ZimmermannDirectorSale2,000$318.17$636KForm 4
Nov 10, 2026Jason AryehDirectorSale500$319.99$160KForm 4
Nov 10, 2026Jason AryehDirectorSale844$320.00$270KForm 4
Nov 10, 2026Jason AryehDirectorSale646$320.00$207KForm 4
Nov 10, 2026Jason AryehDirectorSale10$320.02$3.2KForm 4
Nov 10, 2026Jason AryehDirectorSale500$320.10$160KForm 4
Nov 10, 2026Jason AryehDirectorSale500$320.20$160KForm 4
Nov 4, 2026Jason AryehDirectorSale282$319.99$90.2KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan283$307.39$87KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan708$308.43$218KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan522$309.91$162KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan490$310.61$152KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan520$311.72$162KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan634$312.85$198KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan403$313.75$126KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan80$314.58$25.2KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan280$317.91$89KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan440$318.73$140KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan320$319.97$102KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan200$321.44$64.3KForm 4
Nov 2, 2026Andrew ReardonCLO & SecretarySale plan120$323.14$38.8KForm 4
Nov 2, 2026Jason AryehDirectorSale700$320.43$224KForm 4
Oct 30, 2026Jason AryehDirectorSale50$317.74$15.9KForm 4
Oct 30, 2026Jason AryehDirectorSale50$318.23$15.9KForm 4
Oct 30, 2026Jason AryehDirectorSale52$320.24$16.7KForm 4
Oct 30, 2026Jason AryehDirectorSale1,209$320.42$387KForm 4
Oct 30, 2026Jason AryehDirectorSale50$320.49$16KForm 4
Oct 2, 2026Andrew ReardonCLO & SecretarySale plan833$302.51$252KForm 4
Oct 2, 2026Andrew ReardonCLO & SecretarySale plan1,976$303.54$600KForm 4
Oct 2, 2026Andrew ReardonCLO & SecretarySale plan1,535$304.52$467KForm 4
Oct 2, 2026Andrew ReardonCLO & SecretarySale plan404$306.18$124KForm 4
Oct 2, 2026Andrew ReardonCLO & SecretarySale plan235$307.19$72.2KForm 4
Oct 2, 2026Andrew ReardonCLO & SecretarySale plan17$307.74$5.2KForm 4
Sep 10, 2026Martine ZimmermannDirectorSale1,200$285.00$342KForm 4
Sep 3, 2026Andrew ReardonCLO & SecretarySale plan385$287.53$111KForm 4
Sep 3, 2026Andrew ReardonCLO & SecretarySale plan1,800$285.17$513KForm 4
Sep 3, 2026Andrew ReardonCLO & SecretarySale plan2,115$286.36$606KForm 4
Sep 3, 2026Andrew ReardonCLO & SecretarySale plan300$283.99$85.2KForm 4
Sep 3, 2026Andrew ReardonCLO & SecretarySale plan400$288.98$116KForm 4
Aug 12, 2026Octavio EspinozaCFOSale plan31,641$292.07$9.2MForm 4
Aug 12, 2026Jason HaasDirectorSale7,138$292.81$2.1MForm 4
Aug 3, 2026Andrew ReardonCLO & SecretarySale plan200$290.60$58.1KForm 4
Aug 3, 2026Andrew ReardonCLO & SecretarySale plan991$291.71$289KForm 4
Aug 3, 2026Andrew ReardonCLO & SecretarySale plan409$292.82$120KForm 4
Aug 3, 2026Andrew ReardonCLO & SecretarySale plan105$284.14$29.8KForm 4
Aug 3, 2026Andrew ReardonCLO & SecretarySale plan33$284.55$9.4KForm 4
Aug 3, 2026Andrew ReardonCLO & SecretarySale plan157$285.74$44.9KForm 4
Aug 3, 2026Andrew ReardonCLO & SecretarySale plan1,032$286.80$296KForm 4
Aug 3, 2026Andrew ReardonCLO & SecretarySale plan1,214$287.77$349KForm 4
Aug 3, 2026Andrew ReardonCLO & SecretarySale plan356$288.75$103KForm 4
Aug 3, 2026Andrew ReardonCLO & SecretarySale plan503$289.80$146KForm 4
Jul 1, 2026Andrew ReardonCLO & SecretarySale plan600$317.15$190KForm 4
Jul 1, 2026Andrew ReardonCLO & SecretarySale plan900$315.78$284KForm 4
Jul 1, 2026Andrew ReardonCLO & SecretarySale plan100$314.58$31.5KForm 4
Jul 1, 2026Andrew ReardonCLO & SecretarySale plan700$313.46$219KForm 4
Jul 1, 2026Andrew ReardonCLO & SecretarySale plan1,081$312.28$338KForm 4
Jul 1, 2026Andrew ReardonCLO & SecretarySale plan1,119$311.72$349KForm 4
Jul 1, 2026Andrew ReardonCLO & SecretarySale plan104$310.20$32.3KForm 4
Jul 1, 2026Andrew ReardonCLO & SecretarySale plan396$308.99$122KForm 4
Jun 16, 2026Stephen L SabbaDirectorSale2,145$254.00$545KForm 4
Jun 12, 2026Jason HaasDirectorSale3,461$256.08$886KForm 4
Jun 12, 2026Jason HaasDirectorSale3,000$255.01$765KForm 4
Jun 11, 2026Jason AryehDirectorSale4,500$250.00$1.1MForm 4
Jun 10, 2026Jason AryehDirectorSale500$250.00$125KForm 4
Jun 10, 2026John L LamattinaDirectorSale257$247.22$63.5KForm 4
Jun 10, 2026John L LamattinaDirectorSale3,405$251.62$857KForm 4
Jun 10, 2026John L LamattinaDirectorSale697$249.53$174KForm 4
Jun 10, 2026John L LamattinaDirectorSale232$248.11$57.6KForm 4
Jun 1, 2026Andrew ReardonCLO & SecretarySale plan491$223.95$110KForm 4
Jun 1, 2026Andrew ReardonCLO & SecretarySale plan677$225.20$152KForm 4
Jun 1, 2026Andrew ReardonCLO & SecretarySale plan1,432$225.97$324KForm 4
Jun 1, 2026Andrew ReardonCLO & SecretarySale plan400$226.78$90.7KForm 4
Jun 1, 2026Andrew ReardonCLO & SecretarySale plan584$228.57$133KForm 4
Jun 1, 2026Andrew ReardonCLO & SecretarySale plan200$230.41$46.1KForm 4
Jun 1, 2026Andrew ReardonCLO & SecretarySale plan1,216$229.47$279KForm 4
May 13, 2026John W KozarichDirectorSale plan1,575$223.50$352KForm 4
May 12, 2026John W KozarichDirectorSale plan459$224.00$103KForm 4
May 1, 2026John W KozarichDirectorSale plan1$229.87$230Form 4
May 1, 2026John W KozarichDirectorSale plan165$231.87$38.3KForm 4
May 1, 2026John W KozarichDirectorSale plan105$232.57$24.4KForm 4
May 1, 2026John W KozarichDirectorSale plan116$234.09$27.2KForm 4
May 1, 2026John W KozarichDirectorSale plan80$227.37$18.2KForm 4
May 1, 2026Andrew ReardonCLO & SecretarySale plan98$229.71$22.5KForm 4
May 1, 2026Andrew ReardonCLO & SecretarySale plan370$230.87$85.4KForm 4
May 1, 2026Andrew ReardonCLO & SecretarySale plan1,420$232.92$331KForm 4
May 1, 2026Andrew ReardonCLO & SecretarySale plan800$234.02$187KForm 4
May 1, 2026Andrew ReardonCLO & SecretarySale plan932$228.75$213KForm 4
May 1, 2026Andrew ReardonCLO & SecretarySale plan600$227.45$136KForm 4
May 1, 2026Andrew ReardonCLO & SecretarySale plan780$232.04$181KForm 4
Apr 1, 2026John W KozarichDirectorSale plan43$202.91$8.7KForm 4
Apr 1, 2026John W KozarichDirectorSale plan79$202.42$16KForm 4
Apr 1, 2026John W KozarichDirectorSale plan40$201.24$8KForm 4
Apr 1, 2026John W KozarichDirectorSale plan146$199.97$29.2KForm 4
Apr 1, 2026John W KozarichDirectorSale plan159$204.26$32.5KForm 4
Apr 1, 2026Andrew ReardonCLO & SecretarySale plan460$198.85$91.5KForm 4
Apr 1, 2026Andrew ReardonCLO & SecretarySale plan1,302$199.72$260KForm 4
Apr 1, 2026Andrew ReardonCLO & SecretarySale plan1,238$200.94$249KForm 4
Apr 1, 2026Andrew ReardonCLO & SecretarySale plan700$201.90$141KForm 4
Apr 1, 2026Andrew ReardonCLO & SecretarySale plan963$203.22$196KForm 4

Latest 100 of 151 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Octavio EspinozaChief Financial Officer–$13MAug 12, 2026
Andrew ReardonCLO & Secretary–$11.9MNov 2, 2026
Jason HaasDirector–$3.7MAug 12, 2026
Jason AryehDirector–$3MNov 10, 2026
John L LamattinaDirector–$1.6MJun 10, 2026
John W KozarichDirector–$1.2MNov 12, 2026
Stephen L SabbaDirector–$1.2MJun 16, 2026
Martine ZimmermannDirector–$978KNov 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LGND short interest

High short interest. 12.3% of LGND shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 64%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.46M LGND shares were sold short, 12.3% of the shares outstanding, down 1.5% from the report before. At the average daily volume of 234,088 shares, buying them all back would take about 10.5 trading days (days to cover).

Shares short, % of all shares

12.3%May 15Oct 3014.3%

Days to cover

10.5May 15Oct 3015.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.46M12.32%-2%234,08810.5
Oct 15, 20262.50M12.55%-7%237,67710.5
Sep 30, 20262.68M13.43%+2%306,6508.7
Sep 15, 20262.63M13.20%+6%194,50913.5
Aug 31, 20262.48M12.44%+1%175,76414.1
Aug 14, 20262.45M12.28%+13%279,4238.8
Jul 31, 20262.17M10.83%+13%294,5877.4
Jul 15, 20261.92M9.57%-10%384,5865.0
Jun 30, 20262.12M10.59%+26%814,8372.6
Jun 15, 20261.69M8.43%+3%202,9058.3
May 29, 20261.64M8.18%+9%200,3708.2
May 15, 20261.51M7.51%+3%225,6826.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded LGND

Since Nov 17, 2024, 1 member of Congress reported 4 purchases and 0 sales of LGND. The latest was a purchase by Gilbert Ray Cisneros, Jr. on May 29, 2026, reported Jun 8, 2026.

Purchases 4Sales 0

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
May 29, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfJun 8, 2026Report
Mar 3, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfApr 7, 2026Report
Jan 15, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfFeb 13, 2026Report
Jan 5, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfFeb 13, 2026Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Ligand Pharmaceuticals company events

Ligand Pharmaceuticals filed 14 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026ResultsReleased financial results. Filing
  2. Sep 24, 2026AnnouncementShared information with investors. Filing
  3. Sep 22, 2026AnnouncementShared information with investors. Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. Jul 14, 2026DealThe information contained in the first paragraph of item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. Filing
  6. Jun 25, 2026AgreementLigand Pharmaceuticals Incorporated completed its previously announced private offering of $700.0 million of 0.00% Convertible Senior Notes due 2031, including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million of Notes. Filing
  7. Jun 22, 2026AgreementIn connection with the Offering (as defined below), on June 22, 2026, Ligand Pharmaceuticals Incorporated, as borrower, entered into a Consent and Fourth Amendment to Credit Agreement with certain of the Company’s subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein)… Filing
  8. Jun 9, 2026LeadershipThe 2026 Annual Meeting of the Stockholders of Ligand Pharmaceuticals Incorporated was held on June 5, 2026. Filing
  9. May 18, 2026AgreementAs previously disclosed, on April 27, 2026, Ligand Pharmaceuticals Incorporated, a Delaware corporation, entered into an Agreement and Plan of Merger, by and among Ligand, XOMA Royalty Corporation, a Nevada corporation, and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of… Filing
  10. May 7, 2026ResultsReleased financial results. Filing
  11. Apr 30, 2026AgreementEnded an important agreement. Filing
  12. Apr 27, 2026AgreementLigand Pharmaceuticals Incorporated, a Delaware corporation, entered into an Agreement and Plan of Merger, by and among Ligand, XOMA Royalty Corporation, a Nevada corporation, and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Ligand, pursuant to which, and upon the… Filing
  13. Feb 26, 2026ResultsReleased financial results. Filing
  14. Dec 18, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Ligand Pharmaceuticals financials

Famous investors that hold LGND

5 of the 50 well-known investors we track reported holding LGND in their latest 13F filing. The largest position is Ken Fisher's, worth $40.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 2026128,643$40.2M0.0%+6%
Ken Griffin · Citadel AdvisorsQ3 202633,304$10.4M0.0%New
Ray Dalio · Bridgewater AssociatesQ3 20269,763$3M0.0%New
Jim Simons · Renaissance TechnologiesQ3 20267,094$2.2M0.0%New
Israel Englander · Millennium ManagementQ3 20261,336$417K0.0%-66%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named LGND in the last 120 days.

FiledHolderFormStake
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A4.6%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A4.6%
Nov 10, 2026Invesco Ltd.13G/A7.6%
Nov 10, 2026Invesco Ltd.13G/A7.6%

Questions about Ligand Pharmaceuticals Inc (LGND) stock

Who owns the most LGND stock?

The largest reported owner of Ligand Pharmaceuticals Inc (LGND) is BlackRock, Inc., with 15.5% of the company. In total, 414 funds and institutions reported holding LGND at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are LGND insiders buying or selling?

In the last 12 months, LGND insiders reported no open-market purchases and 151 sales worth $36.5M. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in LGND?

As of Oct 30, 2026, 2.46M LGND shares were sold short, 12.3% of the shares outstanding, down 1.5% from the report before. At the average daily volume of 234,088 shares, buying them all back would take about 10.5 trading days (days to cover). See the history.

Have members of Congress traded LGND?

Yes. 1 member of Congress reported 4 purchases and 0 sales of LGND since Nov 17, 2024. The latest was reported on Jun 8, 2026. See the trades.

Which famous investors hold LGND?

5 of the 50 well-known investors we track reported LGND in their latest 13F filing, including Ken Fisher, Ken Griffin, Ray Dalio. The largest position is worth $40.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.